Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Zosurabalpin in Critically Ill Patients with Bacterial Infections
NCT05614895Phase 1Completed
- Sponsor
- Roche
- Start
- Dec 2022
- Primary completion
- Jan 2024
- Modality
- Cyclic Peptides
- Countries
- 5
01
Overview
Phase 1, open-label trial of zosurabalpin in bacterial infection, hospital-acquired bacterial pneumonia (HAP), ventilator-associated pneumonia (VAP) and 1 more (4 arms), sponsored by Roche. Primary endpoint: Plasma Concentrations of RO7223280. Started Dec 2022; status: completed.
02
Drugs
zosurabalpin
03
Conditions
bacterial infectionhospital-acquired bacterial pneumonia (HAP)ventilator-associated pneumonia (VAP)Bacteremia
Beyond the preview
Go deeper on NCT05614895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05614895.